UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 01/2018, Volume 73, Issue suppl_1, pp. i2 - i3
Journal Article
Journal of antimicrobial chemotherapy, ISSN 0305-7453, 03/2017, Volume 72, Issue suppl_1, pp. i39 - i47
Pharmacology & Pharmacy | Infectious Diseases | Life Sciences & Biomedicine | Microbiology | Science & Technology | Lung Diseases, Fungal - diagnosis | Humans | Critical Illness | Aspergillosis - diagnosis | Respiratory System - microbiology | Aspergillosis - epidemiology | Lung Diseases, Fungal - microbiology | Antifungal Agents - therapeutic use | Invasive Fungal Infections - drug therapy | Aspergillus - isolation & purification | Mucormycosis - drug therapy | Aspergillosis - drug therapy | Pyridines - therapeutic use | Triazoles - therapeutic use | Intensive Care Units | Mucormycosis - epidemiology | Mucormycosis - diagnosis | Voriconazole - therapeutic use | Invasive Fungal Infections - diagnosis | Aspergillus - drug effects | Opportunistic Infections - diagnosis | Opportunistic Infections - microbiology | beta-Glucans - blood | Mucor - isolation & purification | Mannans - blood | Opportunistic Infections - drug therapy | Immunocompromised Host | Invasive Fungal Infections - microbiology | Mucor - drug effects | Nitriles - therapeutic use | Index Medicus
Journal Article
Current opinion in infectious diseases, ISSN 0951-7375, 04/2018, Volume 31, Issue 2, pp. 103 - 103
Journal Article
Annals of clinical microbiology and antimicrobials, ISSN 1476-0711, 08/2013, Volume 12, Issue 1, pp. 22 - 22
Resistance | EMA | Bacteria | FDA | New antibiotics | Life Sciences & Biomedicine | Microbiology | Science & Technology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Bacterial Infections - drug therapy | Drug Resistance, Multiple, Bacterial | Humans | Bacteria - drug effects | Drugs, Investigational - therapeutic use | Drug Approval | Drug Discovery | Moxalactam | Drug resistance in microorganisms | Pneumonia | Bacterial infections | Cephalosporins | United States | Bacterial pneumonia | Mortality | Staphylococcal infections | Development and progression | Cephaloridine | Staphylococcus infections | Antibiotics | Bacteriology | Aminoglycoside antibiotics | Index Medicus
Journal Article
Current opinion in infectious diseases, ISSN 0951-7375, 12/2018, Volume 31, Issue 6, pp. 587 - 593
Journal Article
Langenbeck's archives of surgery, ISSN 1435-2443, 2/2015, Volume 400, Issue 2, pp. 153 - 165
FDA | Medicine & Public Health | Cardiac Surgery | Traumatic Surgery | New antibiotics | Multidrug resistance | Abdominal Surgery | Vascular Surgery | Thoracic Surgery | General Surgery | Life Sciences & Biomedicine | Surgery | Science & Technology | Bacterial Infections - drug therapy | United States | Humans | Drugs, Investigational - therapeutic use | Drug Discovery - methods | Male | Drug Approval | Infection Control - methods | Forecasting | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Clinical Trials, Phase III as Topic | Female | Anti-Bacterial Agents - pharmacology | Drug Resistance, Multiple, Bacterial - drug effects | Bacterial Infections - microbiology | United States Food and Drug Administration | Clinical Trials, Phase II as Topic | Moxalactam | Pneumonia | Hospitals | Cephalosporins | Bacterial pneumonia | Mortality | Bacteria | Cephaloridine | Drug resistance | Index Medicus
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 10/2019, Volume 19, Issue 10, pp. 1037 - 1039
Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Linezolid | Pathogens | Therapy | Clinical trials | Staphylococcus infections | Infections | Drug resistance | Patients | Studies | Antibiotics | Population | Bacteria | Skin | Gram-negative bacteria | Drug dosages | Index Medicus
Journal Article
Expert opinion on investigational drugs, ISSN 1354-3784, 11/2014, Volume 23, Issue 11, pp. 1575 - 1584
new antibiotics | abdominal infections | bacteria | eravacycline | Eravacycline | Bacteria | New antibiotics | Abdominal infections | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Tetracyclines - administration & dosage | Administration, Oral | Intraabdominal Infections - microbiology | Humans | Gram-Negative Bacterial Infections - drug therapy | Gram-Negative Bacterial Infections - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Animals | Drug Resistance, Multiple, Bacterial | Gram-Positive Bacterial Infections - microbiology | beta-Lactams - adverse effects | Anti-Bacterial Agents - adverse effects | Tetracyclines - adverse effects | Gram-Positive Bacterial Infections - drug therapy | beta-Lactams - therapeutic use | Anti-Bacterial Agents - administration & dosage | Intraabdominal Infections - drug therapy | Tetracyclines - therapeutic use | beta-Lactams - administration & dosage | Index Medicus
Journal Article
Nutrition (Burbank, Los Angeles County, Calif.), ISSN 0899-9007, 11/2020, Volume 79-80, pp. 110967 - 110967
COVID-19 | Alveolar cell type II | Obesity | Hyperglycemia | Interferon type I | Cytokine storm syndrome | Disseminated intravascular coagulation | Aerobic glycolysis | Diabetes | Ketogenic diet | Macrophage | Warburg effect | Pandemics | Cytokines - metabolism | Humans | Lactic Acid - metabolism | Blood Platelets | Neutrophils | Disseminated Intravascular Coagulation | Ketosis | Diabetes Mellitus | Energy Intake | Inflammation - etiology | Hyperglycemia - metabolism | Inflammation - metabolism | Macrophages - metabolism | Monocytes | SARS-CoV-2 | COVID-19 - metabolism | COVID-19 - complications | Glycolysis | Interferon Type I - metabolism | Inflammation - prevention & control | Blood Glucose - metabolism | Ketones - metabolism | Diet, Carbohydrate-Restricted | Life Sciences & Biomedicine | Nutrition & Dietetics | Science & Technology | Care and treatment | Coronaviruses | Biological response modifiers | Macrophages | Fatty acids | Prevention | Lactates | Glucose metabolism | Physiological aspects | Interferon | Health aspects | Adenosine triphosphate | Disease | Viral diseases | Coagulation | Glucose | Blood | Proteins | Genotype & phenotype | Low carbohydrate diet | Mitochondria | Availability | Carbohydrates | Cytokines | Mortality | Leukocytes (neutrophilic) | Metabolism | Side effects | Diet | Blood circulation | Respiratory distress syndrome | Hypoxia | Oxidative stress | Phosphorylation | Ketogenesis | Viruses | Diabetes mellitus (insulin dependent) | Cytokine storm | High fat diet | Phagocytes | Tumor necrosis factor-TNF | Peroxidase | Oxidation | Hypertension | Phenotypes | Diabetes mellitus | Inflammation | Hypoglycemia | Hypotheses | Oxidative phosphorylation | Exudation | Lactic acid | Platelets | ATP | Chemokines | Viral infections | Index Medicus
Journal Article
Current opinion in infectious diseases, ISSN 0951-7375, 12/2016, Volume 29, Issue 6, pp. 583 - 594
Multidrug-resistant | Klebsiella pneumoniae carbapenemase | Treatment | Extended-spectrum b-lactamase | Enterobacteriaceae | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Enterobacteriaceae - enzymology | Prospective Studies | Enterobacteriaceae Infections - prevention & control | Humans | beta-Lactamases - biosynthesis | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Carbapenems - therapeutic use | Drug Resistance, Multiple, Bacterial | beta-Lactamase Inhibitors - therapeutic use | Enterobacteriaceae - drug effects | Retrospective Studies | Enterobacteriaceae Infections - drug therapy | Index Medicus
Journal Article